Active	Status	Sponsor type	Region	Phase	Filter
1 Active 2 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kraemer, Alwin
CheCUP, NCT04131621 / 2018-004562-33: Nivolumab/Ipilimumab in Second Line CUP-syndrome	Recruiting	2	194	Europe	Nivolumab/Ipilimumab	University Hospital Heidelberg, Bristol-Myers-Squibb	Cancer of Unknown Primary Site	12/22	12/22